News

Metabolic health declining among the obese, despite improvements in BP and lipids


 

FROM THE JOURNAL OF THE AMERICAN HEART ASSOCIATION

References

The study was supported by the Department of Veterans Affairs, the National Institutes of Health, and the University of Alabama Diabetes Research Center.

Dr. Guo had no financial disclosures. Dr. Garvey disclosed relationships with multiple pharmaceutical companies.

msullivan@frontlinemedcom.com

Pages

Recommended Reading

Strong gender difference for stroke in diabetes patients with restless legs syndrome
MDedge Cardiology
Strong gender difference for stroke in diabetes patients with restless legs syndrome
MDedge Cardiology
FDA strengthens kidney warnings on two diabetes drugs
MDedge Cardiology
Empagliflozin slows renal disease progression in type 2 diabetes
MDedge Cardiology
Pioglitazone safe and effective for steatohepatitis in T2DM
MDedge Cardiology
LEADER: Liraglutide lowers CVD risk in type 2 diabetes
MDedge Cardiology
Menopause and cardiovascular risk examined in type 1 diabetes
MDedge Cardiology
FDA panel narrowly endorses empagliflozin’s cardiovascular mortality benefit
MDedge Cardiology
What difference would an empagliflozin CVD indication make?
MDedge Cardiology
Statement warns of drugs causing or exacerbating heart failure
MDedge Cardiology